(3R)-6-fluoro-3-(3-pyrrolidinyl)-1H-indole | 220901-97-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3R)-6-fluoro-3-(3-pyrrolidinyl)-1H-indole
• 英文别名: 3-{6-fluoro-indol-3-yl}-pyrrolidine；6-fluoro-3-pyrrolidin-3-yl-1H-indole
• CAS: 220901-97-3
• 化学式: C₁₂H₁₃FN₂
• 分子量: 204.247
• InChiKey: BVCGGWSWVISFKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3R)-6-fluoro-3-(3-pyrrolidinyl)-1H-indole 生成 1-{2-[(3R)-3-(6-Fluoro-1H-indol-3-yl)pyrrolidinyl]ethyl}-3,4-dihydro-1H-2-benzopyran-6-carboxamide
  参考文献：
  名称：

  Pharmaceutical compounds

  摘要：

  这项发明涉及到式(I)的化合物，其中R1至R12，—W—V—，—X—Y—，m和n的值如权利要求1中定义的，它们的制备和用作药物。

  公开号：

  US20040122001A1
• 作为产物：
  描述：

  3-(6-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以65 %的产率得到(3R)-6-fluoro-3-(3-pyrrolidinyl)-1H-indole
  参考文献：
  名称：

  [EN] RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE RAS, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI

  摘要：

  There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS. (I)

  公开号：

  WO2023060362A1

文献信息

• Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands
  申请人：ELI LILLY AND COMPANY LIMITED

  公开号：EP0897921A1

  公开（公告）日：1999-02-24

  Compounds having the formula: in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R1 and R2 are each hydrogen or C1-4 alkyl, R3, R4 and R5 are each hydrogen, C1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C1-4 alkyl, or R3 and R4 together form an alkylene link of formula -(CH2)3- or -(CH2)4-, or R4 and R5 together with the carbon atom to which they are attached form a C3-6 cycloalkyl group, R6 is C1-4 alkyl, C1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof, are binding to the 5-HT serotonin receptor and are useful in the treatment of CNS disorders.

  具有以下化学式的化合物： 其中n为1或2，m为1或2， p为1至6，q为0或1至3， R1和R2分别为氢或C1-4烷基， R3、R4和R5分别为氢、C1-4烷基、可选择取代的苯基或可选择取代的苯基-C1-4烷基，或者R3和R4一起形成化学式-(CH2)3-或-(CH2)4-的烷基链，或者R4和R5与它们连接的碳原子一起形成C3-6环烷基团， R6为C1-4烷基、C1-4烷氧基、羧基、羟基、氰基、卤素、三氟甲基、硝基或氨基， 虚线表示可选的双键，和 氟原子连接在6位或7位； 以及它们的盐和酯，与5-HT血清素受体结合，并在中枢神经系统疾病的治疗中有用。
• [EN] PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY<br/>[FR] COMPOSES PHARMACEUTIQUES A ACTIVITE DE RECEPTEUR DE SEROTONINE
  申请人：LILLY CO ELI

  公开号：WO2003006455A1

  公开（公告）日：2003-01-23

  This invention relates to compounds of formula (I) wherein R2 to R10, -X-Y-, A, -W-, n and p have the values defined in claim 1, their preparation and use as pharmaceuticals.

  本发明涉及式（I）的化合物，其中R2到R10，-X-Y-，A，-W-，n和p具有权利要求书中定义的值，其制备方法以及作为药物的用途。
• Isochroman compounds for treatment of cns disorders
  申请人：Agejas-Chicharro Javier

  公开号：US20050014750A1

  公开（公告）日：2005-01-20

  This invention relates to compounds of formula (I) where R1 to R12, —W—V—, —X—Y—, p and n have the values defined in claim 1, their preparation and use as pharmaceuticals.

  本发明涉及公式（I）的化合物，其中R1到R12，-W-V-，-X-Y-，p和n具有权利要求1中定义的值，它们的制备和用作药物。
• Pharmaceutical compounds with serotonin receptor activity
  申请人：——

  公开号：US20040180883A1

  公开（公告）日：2004-09-16

  This invention relates to compounds of formula (I) wherein R2 to R10, —X—Y—, A, —W—, n and p have the values defined in claim 1 , their preparation and use as pharmaceuticals.

  本发明涉及一种式子为(I)的化合物，其中R2到R10，—X—Y—，A，—W—，n和p具有权利要求1中定义的值，其制备和用作药物。
• 1H-2,1,3-benzothiadiazine-2,2-dioxide compounds or derivatives thereof
  申请人：Eli Lilly and Company Limited

  公开号：US05929072A1

  公开（公告）日：1999-07-27

  A pharmaceutical compound having the formula: ##STR1## in which n is 1 or 2, m is 1 or 2, p is 1 to 6, q is 0 or 1 to 3, R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-4 alkyl, R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted phenyl-C.sub.1-4 alkyl, or R.sup.3 and R.sup.4 together form an alkylene link of formula --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 --, or R.sup.4 and R.sup.5 together with the carbon atom to which they are attached form a C.sub.3-6 cycloalkyl group, R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, carboxy, hydroxy, cyano, halo, trifluoromethyl, nitro or amino, the dotted line represents an optional double bond, and the fluorine atom is attached at the 6 or 7-position; and salts and esters thereof.

  一种具有以下式子的药物化合物：##STR1## 其中n为1或2，m为1或2，p为1到6，q为0或1到3，R.sup.1和R.sup.2分别为氢或C.sub.1-4烷基，R.sup.3，R.sup.4和R.sup.5分别为氢，C.sub.1-4烷基，可选取代苯基或可选取代苯基-C.sub.1-4烷基，或R.sup.3和R.sup.4一起形成式子--(CH.sub.2).sub.3--或--(CH.sub.2).sub.4--的烷基链，或R.sup.4和R.sup.5与它们连接的碳原子一起形成C.sub.3-6环烷基，R.sup.6为C.sub.1-4烷基，C.sub.1-4烷氧基，羧基，羟基，氰基，卤素，三氟甲基，硝基或氨基，虚线表示可选的双键，氟原子附着在6或7位；以及其盐和酯。